Grifols (NASDAQ:GRFS) Sets New 52-Week Low – What’s Next?

Grifols, S.A. (NASDAQ:GRFS)’s share price reached a new 52-week low on Tuesday . The stock traded as low as $7.07 and last traded at $7.0730, with a volume of 555410 shares traded. The stock had previously closed at $7.33.

Wall Street Analyst Weigh In

Several research firms have commented on GRFS. Zacks Research lowered shares of Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Weiss Ratings lowered Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Finally, Wall Street Zen cut Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $10.00.

Grifols Trading Down 3.1%

The company has a quick ratio of 0.85, a current ratio of 2.47 and a debt-to-equity ratio of 1.16. The firm has a 50 day moving average of $7.80 and a 200 day moving average of $8.45. The firm has a market cap of $4.84 billion, a PE ratio of 37.39, a P/E/G ratio of 0.29 and a beta of 0.65.

Grifols (NASDAQ:GRFS) last released its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share (EPS) for the quarter. The business had revenue of $2.32 billion during the quarter. Grifols had a return on equity of 6.21% and a net margin of 5.54%. Equities analysts anticipate that Grifols, S.A. will post 1.06 earnings per share for the current year.

Grifols Dividend Announcement

The firm also recently disclosed a special dividend, which will be paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.0945 per share. The ex-dividend date of this dividend is Thursday, July 2nd. Grifols’s dividend payout ratio is 73.68%.

Institutional Trading of Grifols

Several hedge funds and other institutional investors have recently modified their holdings of GRFS. Royal Bank of Canada boosted its holdings in Grifols by 21.7% in the 1st quarter. Royal Bank of Canada now owns 486,824 shares of the biotechnology company’s stock worth $3,461,000 after buying an additional 86,768 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Grifols during the 1st quarter valued at $184,000. Goldman Sachs Group Inc. lifted its position in shares of Grifols by 1.9% during the first quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock worth $29,948,000 after acquiring an additional 80,507 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Grifols by 127.4% during the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 4,604 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in shares of Grifols by 11.6% in the second quarter. Sei Investments Co. now owns 2,081,535 shares of the biotechnology company’s stock worth $18,817,000 after acquiring an additional 216,793 shares during the period.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.